Our Investment Focus & Portfolio

Aignostics, a spin-off from Charité – Universitätsmedizin Berlin and the Berlin Institute of Health, is pioneering computational pathology for pharmaceutical research and diagnostics. Its proprietary "Explainable AI" platform draws on research from Fraunhofer Society, Charité, and TU Berlin to overcome the typical "black-box" problem of AI in pathology. Aignostics' focus lies on developing bespoke AI models for clinical trials and CDx development.

Bodyport’s mission is to prevent and ultimately eliminate heart disease by empowering every person with high quality, actionable health information in their home.

Brainomix, Ltd. focuses on imaging software for neurological and cerebrovascular diseases and developed a software tool (e-ASPECTS) for the automated analysis of CT scans to detect early ischemic changes in the brain of patients with clinical signs of stroke. Brainomix is a spin-out from the University of Oxford, UK.

C-mo Medical Solutions is a Digital Health start-up that develops solutions for the diagnosis and management of cough-incident medical conditions. The company’s mission is to unravel the clinical potential of cough assessment and solve the bold unmet medical need associated with the management of chronic cough.

Dopavision GmbH is developing a digital therapeutic for myopia which can be seamlessly and invisibly integrated while using a smartphone. The technology projects a light stimulus from a screen (e.g., a smartphone) into the eye to activate a neurotransmitter cascade which influences the correct development of the eyeball and thereby correct vision. Dopavision is headquartered in Berlin, Germany.

Optina Diagnostics specializes in the development of technology for early, non-invasive detection of disease via Retinal Deep Phenotyping^TM. With an initial primary focus on the diagnosis of Alzheimer’s disease, Optina addresses the pressing need of millions of patients worldwide suffering from memory loss.

Perfood analyzes glycemic responses to meals, activity, symptoms, medication and gut microbiome on the basis of machine learning algorithms. This results in a pipeline of digital therapeutics based on personalized low-glycemic diet. At the same time, Perfood builds up a rich dataset for phenotyping.

Wellth, Inc. applies behavioral economics through a mobile first, financial incentive focused behavior change platform to achieve better adherence, engagement, and health. The solution serves the most common chronic conditions. Wellth is headquartered in Brooklyn, NY.

The xCures platform transforms complex unstructured medical data directly from the patient’s medical records into structured data suitable for analysis and machine learning. Our A.I. engine then actively cross-references this data against the vast digital library of oncology data to match patients with potential treatments and predict outcomes. This empowers patients and their oncologists to make more informed and effective treatment decisions.